TARS logo

Tarsus Pharmaceuticals, Inc. (TARS) EBIT

Annual EBIT:

-$108.11M+$24.56M(+18.51%)
December 31, 2024

Summary

  • As of today, TARS annual earnings before interest & taxes is -$108.11 million, with the most recent change of +$24.56 million (+18.51%) on December 31, 2024.
  • During the last 3 years, TARS annual EBIT has fallen by -$94.33 million (-684.98%).
  • TARS annual EBIT is now -7907.93% below its all-time high of -$1.35 million, reached on December 31, 2018.

Performance

TARS EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

Quarterly EBIT:

-$14.53M+$7.66M(+34.51%)
September 30, 2025

Summary

  • As of today, TARS quarterly earnings before interest & taxes is -$14.53 million, with the most recent change of +$7.66 million (+34.51%) on September 30, 2025.
  • Over the past year, TARS quarterly EBIT has increased by +$10.63 million (+42.26%).
  • TARS quarterly EBIT is now -235.61% below its all-time high of $10.71 million, reached on March 31, 2021.

Performance

TARS Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

TTM EBIT:

-$87.41M+$10.63M(+10.84%)
September 30, 2025

Summary

  • As of today, TARS TTM earnings before interest & taxes is -$87.41 million, with the most recent change of +$10.63 million (+10.84%) on September 30, 2025.
  • Over the past year, TARS TTM EBIT has increased by +$53.18 million (+37.83%).
  • TARS TTM EBIT is now -13709.48% below its all-time high of -$633.00 thousand, reached on September 30, 2019.

Performance

TARS TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

TARS EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+18.5%+42.3%+37.8%
3Y3 Years-685.0%+36.6%-40.7%
5Y5 Years-2415.3%-43.3%-613.1%

TARS EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-685.0%+18.5%at high+67.3%-40.7%+44.1%
5Y5-Year-2415.3%+18.5%-235.6%+67.3%-2323.4%+44.1%
All-TimeAll-Time-7907.9%+18.5%-235.6%+67.3%>-9999.0%+44.1%

TARS EBIT History

DateAnnualQuarterlyTTM
Sep 2025
-
-$14.53M(+34.5%)
-$87.41M(+10.8%)
Jun 2025
-
-$22.18M(+15.6%)
-$98.05M(+10.2%)
Mar 2025
-
-$26.28M(-7.6%)
-$109.17M(+9.5%)
Dec 2024
-$108.11M(+18.5%)
-$24.42M(+2.9%)
-$120.57M(+14.2%)
Sep 2024
-
-$25.16M(+24.4%)
-$140.60M(+10.1%)
Jun 2024
-
-$33.30M(+11.6%)
-$156.37M(-0.3%)
Mar 2024
-
-$37.68M(+15.2%)
-$155.89M(-8.9%)
Dec 2023
-$132.67M(-121.0%)
-$44.45M(-8.6%)
-$143.16M(-25.8%)
Sep 2023
-
-$40.94M(-24.7%)
-$113.77M(-18.8%)
Jun 2023
-
-$32.82M(-31.5%)
-$95.74M(-40.5%)
Mar 2023
-
-$24.95M(-65.7%)
-$68.14M(-8.7%)
Dec 2022
-$60.03M
-$15.06M(+34.2%)
-$62.71M(-0.9%)
DateAnnualQuarterlyTTM
Sep 2022
-
-$22.91M(-338.5%)
-$62.12M(-13.1%)
Jun 2022
-
-$5.22M(+73.2%)
-$54.92M(-29.5%)
Mar 2022
-
-$19.52M(-34.9%)
-$42.42M(-248.2%)
Dec 2021
-$13.77M(+49.0%)
-$14.47M(+7.9%)
-$12.18M(-32.8%)
Sep 2021
-
-$15.71M(-315.7%)
-$9.17M(-154.3%)
Jun 2021
-
$7.28M(-32.0%)
-$3.61M(+66.9%)
Mar 2021
-
$10.71M(+193.5%)
-$10.89M(+54.1%)
Dec 2020
-$27.00M(-528.2%)
-$11.46M(-13.0%)
-$23.72M(-93.5%)
Sep 2020
-
-$10.14M(-378.8%)
-$12.26M(-345.6%)
Mar 2020
-
-$2.12M(-234.6%)
-$2.75M(-334.6%)
Dec 2019
-$4.30M(-218.4%)
-
-
Sep 2019
-
-$633.00K
-$633.00K
Dec 2018
-$1.35M
-
-

FAQ

  • What is Tarsus Pharmaceuticals, Inc. annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. annual EBIT year-on-year change?
  • What is Tarsus Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
  • What is Tarsus Pharmaceuticals, Inc. TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. TTM EBIT year-on-year change?

What is Tarsus Pharmaceuticals, Inc. annual earnings before interest & taxes?

The current annual EBIT of TARS is -$108.11M

What is the all-time high annual EBIT for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$1.35M

What is Tarsus Pharmaceuticals, Inc. annual EBIT year-on-year change?

Over the past year, TARS annual earnings before interest & taxes has changed by +$24.56M (+18.51%)

What is Tarsus Pharmaceuticals, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of TARS is -$14.53M

What is the all-time high quarterly EBIT for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is $10.71M

What is Tarsus Pharmaceuticals, Inc. quarterly EBIT year-on-year change?

Over the past year, TARS quarterly earnings before interest & taxes has changed by +$10.63M (+42.26%)

What is Tarsus Pharmaceuticals, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of TARS is -$87.41M

What is the all-time high TTM EBIT for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is -$633.00K

What is Tarsus Pharmaceuticals, Inc. TTM EBIT year-on-year change?

Over the past year, TARS TTM earnings before interest & taxes has changed by +$53.18M (+37.83%)
On this page